proteins on or off contributes to the inability to study massive tracts of biological space.
Despite a path that is fraught with pitfalls, the meeting's organizers see a way out of this darkness. With the ambitious Target 2035 plan, they are calling for a global federation of linked but independent research groups to work together to develop a comprehensive set of small-molecule and antibody probes by 2035.
"It's an enormous challenge, " says Adrian Carter, one of the organizers of the meeting and global head of discovery research coordination at Boehringer Ingelheim. "But it's within reach. "
In part, the possibility of success is due to technological advances in the past 10 years, he says. With the advent of targeted protein degraders, for example, chemists may be able to turn even weakly binding ligands into effective antagonists. DNA-encoded libraries are vastly expanding chemical space and offer the ability to find new ligands. Cryo-electron microscopy is being used to visualize protein-ligand interactions for targets that were previously intractable to structure-guided medicinal chemistry. And powerful computational approaches are making virtual screening more informative than ever before.
But the growing enthusiasm for 'open science' is also key, says Aled Edwards, another Target 2035 architect and Chief Executive of the Structural Genomics Consortium. "Many large pharma companies A probe for every protein Target 2035 -an ambitious open-science proposal to develop a suite of chemical genomics tools to modulate every protein in the proteome -faces many challenges ahead.
now recognize that the initial chemical matter for a new protein is more valuable to society and to industry when it is treated as a public resource, " says Edwards. Unburdened by intellectual property concerns, biopharma researchers are increasingly willing to work with the academic community to expand the probe toolbox, reducing redundant research efforts and sharing lessons learned along the way.
Carter and his industry and academic colleagues are now in late-stage discussions with the European Innovative Medicines Initiative (IMI) to launch a public-private partnership to start working towards Target 2035's vision. A proposed €58 million partnership -which will likely consist of five pharmaceutical firms and associated academic partners including some existing members of the Structural Genomics Consortiumcould begin generating an open-science chemogenomics library of 5,000 compounds against roughly 1,000 protein targets as soon as early next year.
And others agree that the time is ripe to push the probe development agenda.
"I'm in favour of this proposal, " says Stuart Schreiber, a chemical biologist and co-founder of the Broad Institute, who is not involved in Target 2035. "I think it's the right time for this kind of effort". Schreiber proposed a similar objective in 2005 in Nature Chemical Biology, and feels that the notion of what constitutes a chemical probe has now matured sufficiently for such an effort to advance to the next level (Box 1).
"I'm very supportive of the Target 2035 proposals, " agrees Paul Workman, CEO of the Institute of Cancer Research. "We need a much bigger effort internationally to increase the number of chemical probes overall and to expand the range of protein families covered. " "Even if they got 20% of the way there, it would be a huge success, " adds Ben Cravatt, a chemist at The Scripps Research Institute.
But even enthusiastic probe hunters also have concerns about what would no doubt be a resource-intensive effort.
"The biggest challenge is to successfully turn this into a community effort, " says Tudor Oprea, a translational data scientist at the University of New Mexico. "It will sail or sink based on whether they are able to get people around the world to buy into this. "
Questions around feasibility -and even what is meant by a chemical probe for every protein -also remain vexed.
"Is this goal achievable with the technologies that we have, within any reasonable period of time?" asks Chris Austin, director of the National Center for Advancing Translational Sciences (NCATS). "I'm afraid that my answer to that is no, and certainly not by 2035. And I say that with heavy heart, because I would love it to be otherwise. "
Tools for tool discovery The team behind Target 2035 is well aware of the technology shortfalls. "We've received strong feedback, especially from the academics, that in order to achieve this goal we are going to need major leaps in technology, " says Carter. And the budget for their soon to be launched IMI initiative already reflects this need, with around onethird allocated to technology development (the other two thirds are allocated to probe and chemogenomic library generation, and to infrastructure development).
A few technologies already stand to be game-changing.
Targeted protein degraders, for instance, exploit the ubiquitin-proteasome system (UPS) to get rid of target proteins. These molecular glues bind a target protein with one arm, and an E3 ligase of the UPS with the other, such that the target is tagged with ubiquitin for degradation by the proteasome. In theory, this means that even ligands that bind weakly at non-functional pockets can be converted into potent and long-lasting antagonists. The first targeted degraders hit the clinic earlier this year, and variations on this approach are quickly gaining traction as a medicinal chemistry tool.
"The potential here is sure damn exciting, " says Edwards.
But challenges persist with this new modality. Workman and colleagues estimate that only 11% of the human proteome has been liganded, highlighting just how much of the proteome would be out of reach to targeted degraders if the only barrier was having a ligand in hand (it isn't). And there are also outstanding questions about how to characterize these compounds. "We need to take a good pharmacological step back and think, what is a selective targeted degrader? How do you define that? And how do you create metrics that you can share with the community so that they can use this as a chemical probe, " says Edwards.
Another promising approach is fully functionalized fragments, developed by Cravatt and colleagues. In 2017, he showed how small-molecule fragments that have been tagged to facilitate covalent bond formation with nearby biomolecules and subsequent Box 1 | When is a small molecule a probe?
The definition of a chemical probe has matured over the years, but there is still plenty of room for interpretation.
When the NIH's molecular libraries Program first started generating probes in 2004, for instance, their goal was to find small molecules with "adequate potency and adequate solubility to be useful for in vitro (i.e. cell-based) experimentation" but requiring further optimization for in vivo use.
The first 4 years of the NIH effort generated 64 such 'probes'. But when Tudor oprea, of the University of New Mexico, organized a peer review panel to assess the quality of these compounds, he found that reviewers had high confidence in only half of these probes. Reviewers had low confidence in 25% of these probes, citing innate chemical structure liabilities, non-specific activity profiles and toxicity issues, he reported in Nature Chemical Biology in 2009.
By then, the NIH had already upped its game. In 2007, it set activity thresholds of potency in the 100 nm range, selectivity and aqueous solubility. In 2008, it stipulated that probes must provide an improvement over existing probes for a given target. And probe peer review has since become more commonplace.
The Chemical Probes Portal, set up to provide reviews of small-molecule probes, for example, has not defined rigid criteria and instead relies on a scientific advisory board to review probes. To date, reviewers have assessed nearly 200 small molecules for the portal, giving only around a quarter of these top marks.
The Chemical Probes Portal has not been updated since August 2017, but is set to be reactivated later this year. "We are working hard and expect the portal to become more active again later this year, followed by significant growth in the following years," says Paul Workman, CEO of the Institute of Cancer Research and a board member for the portal.
The team behind the portal has also further fine-tuned its idea of the perfect probe, recommending that researchers test putative probes alongside structurally related small molecules that lack activity as negative controls. "I really like that concept," says Oprea.
The team behind Target 2035, meanwhile, is keeping an open mind about what it would like to see for future probes.
"We don't have to be holier than thou about this," says Carter. "I think certain compromises can be made that will not influence whether a probe is fit for purpose."
Even if they got 20% of the way there, it would be a huge success purification can be used in fragmentbased phenotypic screening. He has since collaborated with researchers at Bristol-Myers Squibb and elsewhere to further tune this technology for ligand and probe discovery, experimenting to understand the impact of different fragment libraries on ligandability.
"People are using this as a way to almost instantly identify druggable pockets, " says Cravatt. "I'm not naive enough to believe that this platform in and of itself will deliver advanced chemical probes for every protein, but I do think it has the potential to substantially expand the number of proteins in a relatively unbiased way. "
But other tools are going to be needed, too. "We've done a lot of innovative work in probe discovery, " says Anton Simeonov, scientific director at NCATS. "But that's still not translating into truly gigantic drops in costs. "
In part this is because whereas medicinal chemists have honed their small-molecule libraries to find binders for GPCRs, protein kinases and ion channels, these libraries tend to become less and less helpful as researchers move further away from known biological space.
"Novel genome space requires novel chemical space, " says Austin.
Other biological challenges may pose even greater bottlenecks.
"When we looked at why projects failed, it was almost never for the reasons that we expected. Often we could develop an assay, get a screen done, identify an active series and do med chem on these things. But what was lacking were reliable secondary assays to show us that these compounds actually had functions, " says Austin.
When you don't know what function a protein has, he explains, it's very difficult to determine whether a putative probe can turn it off.
The NIH's 5-year-old Illuminating the Druggable Genome (IDG) project is attempting to address this knowledge gap. With a budget of around US$13 million per year, the IDG's focus is primarily on understanding the properties and functions of GPCRs, ion channels and protein kinases. But the first 3-year pilot phase of this project found that the amount of missing information across the entire proteome is huge. Around one in three human proteins fall into the dark genome, with nearly nothing known about them, Oprea and his IDG colleagues wrote last year in Nature Reviews Drug Discovery. The IDG data set also shows that selective probes exist for a little under 4% of the proteome.
To make matters worse, figuring out whether a new compound is selective enough to be used as a probe remains complicated and time-intensive work (Box 1). Not only is there no way to characterize a probe against proteins in the dark genome, but resource restrictions often force researchers to take characterization shortcuts.
"People almost by necessity have to remain under the lamp posts. If you're working on kinase inhibitor, you profile it against kinases because you think these are the most important. Nobody profiles a kinase inhibitor against dehydrogenases, " says Simeonov. But they should. Increasing evidence shows that kinase inhibitors have underappreciated activity against nonkinase targets that can contribute to both the therapeutic potential and the toxicity of these compounds.
As a result, many probes are not as selective as the community would like them to be. "That's one of the biggest problems that then leads to unanticipated biology when you throw this thing into an animal model, " he adds.
Herding medicinal chemists
Organizational obstacles could also slow things down.
Target 2035 advocates are backing a two-phase federated approach to filling out the probe repertoire. Under a first phase, from 2020 until 2025, a group of loosely unified but independent groups -backed by different international funderswould start working out a road map for the community.
While the federated group members will be free to self-select families of proteins to focus on during this first phase, they could work together towards mutually useful and shareable technologies. And they will need to work on a centralized system that can collect, curate and disseminate data to the broader community to reduce redundancy and to share newly produced probes with interested researchers.
In a second phase, from 2025 to 2035, Target 2035 proponents envision a more formalized top-down effort that would be organized to fill the remaining probe deficits, while avoiding duplication of effort, consolidating core activities and sharing advances.
A big benefit of this approach is that it readily taps the expertise, funding and vision of existing research organizations. The NIH's IDG, while not explicitly focused on probe development, could lead to probes for GPCRs, ion channels and kinases. The IMI's soon-to-launch open-access probe generation consortium has prioritized E3 ligases and solute carriers, and could also look at other protein families. And the Structural Genomics Consortium has been working since 2008 on, amongst other things, open-access chemical probes for proteins that are involved in epigenetic control.
But, such a federated approach also has its drawbacks.
"They make a call for groups to self-organize, but there needs to be something a little more centralized to get it started, otherwise nothing will happen, " says Schreiber. A fragmented strategy also makes it hard for interested researchers to figure out how to get involved, he says.
Edwards is on the case. "It's super important to allow academics and industry researchers around the world to collaborate, and not to make this into a bunch of little fiefdoms, " he adds.
The difficulties of infrastructure development are not to be overlooked either, adds Simeonov. If probes are to be shared on an open-science basis, someone has to make those compounds and distribute them to the broader research community for them to be of any use. "Just continual resupply of small molecules ends up being a pretty large organizational challenge that can eat up a lot of budget, " he adds.
The NIH's now discontinued Molecular Libraries Programme (MLP) hoped that commercial small-molecule vendors like Sigma and Tocris would cover these costs by selling newly discovered probes to the research community. But of the nearly 400 probes that the MLP generated, only around 40% are commercially available. And most of these are not labelled or described as probes, and are instead just listed as small molecules for sale. While some of the MLP's unavailable or underappreciated probes likely just aren't up to scientific snuff, commercial considerations can be a major limiting factor even for open-science efforts.
"The probes they are willing to stock are the ones which are popular, " says Austin.
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The premise of Target 2035 is that translational research is too focused on the same old proteins. The Matthew principle holds that the rich get richer, which in this case means that well-studied proteins get even better studied. Target 2035, its proponents hope, will shake up this status quo.
"If you look at cool drugs or proteins, papers that describe chemical probes are inevitably one of the top cited papers in that space. In other words, these things have impact, " says Edwards.
Oprea has seen this first hand. In 2006, he published on a GPER-specific agonist that could be used to unravel oestrogen receptor biology. Subsequent studies have since used this probe to link GPER to diabetes, blood pressure and more. "Once the chemical probe becomes available, then people start to find uses for it, " says Oprea. "Before having a chemical probe, nobody has even the ability to ask. " And the open-science approach that Target 2035 is embracing could increase this effect. "You need to break down the barriers to the use of chemical probes. As soon as you start trying to add any sort of intellectual property restriction on them, people don't order them, " says Carter.
Boehringer has already benefitted from dismantling these barriers. The company is one of six firms that distributes high-quality probes on an open-science basis to the research community through the SGC as well as via their own portal. "It's giving us insights into things which we wouldn't have had otherwise, " says Carter. He points to a case in which independent researchers turned Boehringer's open-science BRD9 inhibitor into a targeted protein degrader that is providing new insights into acute myeloid leukaemia.
But is tool disparity really the main reason researchers keep revisiting the same proteins again and again? Or, are other factors more important?
Grant reviewers and journal editors tend to view research proposals and write-ups on previously unexplored proteins with a sceptical eye, points out Milka Kostic, a chemical biology programme director at the Dana-Farber Cancer Institute. While a protein might be understudied because no one was able to interrogate it before, it also might not have attracted attention before because it just doesn't play much of a role in either health or disease, she explains.
Scientific impact and career trajectories are also influenced heavily by publication and citation numbers, despite the flaws with these metrics. So, how will researchers who spend years developing a probe for a protein with unknown function be credited if this protein turns out to be of little relevance?
"There needs to be a change of culture a little bit, because a lot of biology is being done on things that we know a lot about, " says Kostic.
The broader research community also needs to rethink how it uses probes. Despite a desire to frame probes as a one-size-fits-all solution to interrogating biology, even the best probes are only any good when they are used properly. And researchers have shown time and time again that many putative probes fall short of their activity claims. A recent analysis of proposed small-molecule Keap1-NRF2 protein-protein interaction inhibitors found for example that 10 out of 19 such compounds "appear to be garbage", wrote Novartis's Derek Lowe on his In The Pipeline blog.
"Whenever anyone is using a tool, they need to pause and think, is this the right tool? Am I using it at the right concentration? Am I using it in the right cells? And should I trust what a vendor is telling me?" says Kostic.
"The biggest challenge we face is how to find the best ways to increase awareness among the general biomedical research community about how to choose and use high-quality chemical probes in their work, " agrees Workman. "Unfortunately, there are continuing to be very frequent and often high-profile examples of biomedical researchers using non-expert search engines and vendor catalogues that direct them to out of date or frankly flawed reagents. "
The Chemical Probes Portal, which provides reviews of small-molecule probes, has already documented nearly 250 compounds that are often misused as probes. (This portal, which is backed by Workman and Edwards and others, has not been updated for a few years but is set to be rebooted later this year.)
Show me the money Funding for Target 2035 presents its own hurdles.
"The nature of the problem is big enough that we're going to need the big funders across the globe to contribute, " says Carter.
The human genome has ~20,000 protein-coding genes. Although this number ignores gene splicing and post-translational modifications that no doubt push the size of the functional proteome higher, it provides a starting point for the magnitude of the challenges ahead. Carter and colleagues estimate that probe development currently costs on average more than $2 million per small-molecule probe, and so if Target 2035 sets out to develop just a single probe for each of these, the costs are already at over $40 billion, a little more than the NIH's annual budget. Now, functional antibodies may be cheaper to discover for at least some of the ~36% of the proteome that is thought to be secreted or embedded across the cell membrane. If small-molecule probes already exist for 4% of the proteome, that will bring the costs down too. And in some cases, 'probe quality' compounds may not even be necessary or attainable, dropping costs further still.
But at the same time, the research community will need more than just one probe for many targets. Having both agonists and antagonists would be helpful in many cases. And functionally selective probes that can modulate just a subset of a protein's activities will also be on the must-have list for some proteins.
Although specifics are hard to predict, the final bill for Target 2035 will no doubt be staggering. Even the team behind Target 2035 acknowledges in their white paper that this effort could be "prohibitively expensive and, for some technically challenging proteins, perhaps not even possible".
But, back-of-the-envelope calculations can also overstate the challenges ahead. According to Human Genome Project lore, when the NIH first started thinking about a sequencing project in the 1980s, some critics estimated that it would take 130 years to complete with the technologies that were available at the time. As new tools emerged, costs plunged and timelines accelerated. The Human Genome Project was ultimately completed in 13 years, 2 years ahead of schedule, for $2.7 billion, 10% under budget. Moreover, extremely ambitious goals can be galvanizing, say advocates of a concerted and global probe-discovery effort. "Ambition can be scary, " says Kostic. "But it can also be good; it can be invigorating and motivating. "
And this leaves the team behind Target 2035 with room for optimism. "It is a stretch goal, obviously. But, it's not impossible, " says Edwards.
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